argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy | Argenx
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Business Wire
Argenx Files for FDA Approval of Efgartigimod for Generalized MG
Corporate Presentation June 2023
ARGENX SE Form 6-K Current Report Filed 2023-01-09
Genmab expands immunology reach in argenx pact
Genmab enters multiyear antibody partnership with Argenx — MedWatch
Argenx: Next Phase Of Growth With Efgartigimod And ARGX-117 (NASDAQ:ARGX) | Seeking Alpha
argenx | News
argenx Receives the EMA's CHMP Positive Opinion of Efgartigimod for Generalized Myasthenia Gravis
ELITE 2023 Marketing Team VYVGART Brand Launch Team of argenx | PM360
SEC Filing | argenx
Press release on the reopening of trading in ARGENX | FSMA
ARGENX SE - VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
argenx | News
Argenx's Potential Blockbuster Gets FDA Nod for Autoimmune Disease
ITP Support Association - Press release from argenx, they are evaluating: Efgartigimod in ITP: Phase 3 ADVANCE registrational trial initiated evaluating approximately 150 primary ITP patients dosed with 10mg/kg IV efgartigimod for
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis | Business Wire
argenx SE (ARGX) Stock Price, Quote & News - Stock Analysis
argenx Announces U.S. Food and Drug Administration Approval
Press Releases | Argenx
argenx | News
argenx on X: "Today we announced the continuation of our chronic inflammatory demyelinating polyneuropathy (CIDP) program following interim analysis of the Phase 2/3 ADHERE trial. Learn more here: https://t.co/0vgXZk0o0u https://t.co/iv5KRcJfH8" / X
Argenx Follows up Phase III Success with Giant €785M Global Offering
